RetinaVue™ Network

Diabetic retinal exams made SIMPLE and AFFORDABLE for primary care.

Achieve up to 90% DRE compliance in 12 months. Help preserve vision in patients living with diabetes.

RV100_3_percentages

414 million people are living with diabetes. That number will grow to 642 million by 2040.

More than 80% of patients living with diabetes will develop diabetic retinopathy. 

On average, less than half of all diabetics receive potentially vision-saving diabetic retinal exams (DREs). 


Introducing the Welch Allyn RetinaVue Network

retinavue-aquired

Handheld and Desktop Retinal Camera Options

Including Topcon® TRC NW-400 and Welch Allyn RetinaVue™ 100 Imager–world's most advanced, handheld fundus camera.

FDA Listing #D258266
retinavue-network-software

Welch Allyn
RetinaVue™ Network Software

HIPAA-compliant private cloud infrastructure to securely transfer encrypted images and easily review patient results. 

FDA Listing #D150615
retinavue-PC-Dr-Chaum

Welch Allyn 
RetinaVue™ P.C.

Professional interpretation services and comprehensive diagnostic report via a network of board-certified, state-licensed ophthalmologists.

 
2X_RV100_graphic

RetinaVue Network can help achieve up to 90% compliance in 12 months.


Improve Quality Metrics and Revenue 

5_STARS_RetinaVue

Annual retinal examinations are included in the NCQA® HEDIS® ratings program, the Medicare Advantage STAR quality rating program, and Medicare quality ratings program.

 

“In the category of Medicare diabetes retinal screenings, [RetinaVue] helped our client, Summit Medical Group, move from a one-star quality rating to a four-star rating by one of its major insurance providers within one year.”

–Jack Kam, executive leader and chief science & innovation officer for Summit Strategic Solutions

RetinaVue_Edward_Chaum

It is like adding an eye specialist to your team.

“In addition to identifying, classifying and documenting all levels of diabetic retinopathy from very mild to vision threatening, we have also been able to diagnose a surprising assortment of important systemic diseases based on RetinaVue fundus images—including papilledema, hypertension, macular degeneration (AMD), cancer and stroke.”

EDWARD CHAUM, M.D., PH.D.
Chief Medical Officer, RetinaVue P.C.

Request a demo today!